Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Lawrence T. WeissSVP, Chief Legal Officer | AngiodynamicsANGO | Open-market buy | 25/10/21 | 25/10/22 | 10,000 sh | $11.81 | $118,100 | +12.0% |
Stephen A. TrowbridgeEVP and CFO | AngiodynamicsANGO | Open-market buy | 25/10/13 | 25/10/14 | 890 sh | $11.16 | $9,932.4 | +0.3% |
James C. ClemmerPresident and CEO | AngiodynamicsANGO | Open-market buy | 25/10/09 | 25/10/09 | 10,000 sh | $11.15 | $111,500 | +1.1% |
Nighan Warren Jr.SVP Quality and Regulatory | AngiodynamicsANGO | Open-market sale | 25/01/16 | 25/01/17 | 4,060 sh | $12.31 | $49,978.6 | −8.8% |
AngiodynamicsANGO | Open-market buy | 24/10/07–24/10/10 | 24/10/10 | 868 sh2 trades | $6.09avg. | $5,285.12 | +1.9% | |
Stephen A. TrowbridgeEVP and CFO | AngiodynamicsANGO | Open-market buy | 24/10/08 | 24/10/08 | 1,700 sh | $5.86 | $9,962 | +1.0% |
James C. ClemmerPresident and CEO | AngiodynamicsANGO | Open-market buy10b5-1 plan | 24/10/07 | 24/10/08 | 20,000 sh | $6.03 | $120,600 | +3.0% |
James C. ClemmerPresident and CEO | AngiodynamicsANGO | Open-market buy | 24/04/08 | 24/04/08 | 10,000 sh | $6.70 | $67,000 | +1.9% |
Dave HelselSVP Global Operations and R&D | AngiodynamicsANGO | Open-market sale | 23/01/31 | 23/02/01 | 4,633 sh | $12.95 | $59,997.35 | −19.4% |